Report #2824544

Received Feb 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: CA
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Extra dose administered

Symptom narrative

7 patients received a second dose of Arexvy; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in an specified number of patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received the 2nd dose of Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: 7 patients received a second dose of Arexvy). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 14-JAN-2025 Reporter stated that 7 patients received a second dose of Arexvy, which led to extra dose administered. The patients were fine and no more specific information of the patients or the lot numbers and expiration dates of the vaccines were provided.